Felocell 4

Felocell 4 is for vaccination of healthy cats as an aid in preventing feline viral rhinotracheitis (FVR) caused by feline herpesvirus-1, feline respiratory disease caused by feline calicivirus (FCV), feline panleukopaenia (FPL) caused by feline parvovirus, and feline chlamydophilosis caused by Chlamydophila felis.

Felocell 4 contains attenuated strains of feline rhinotracheitis virus, calicivirus and panleukopaenia virus (Johnson Snow Leopard strain), and C. felis, propagated on established cell lines.

• Felocell 4 is well tolerated as demonstrated in laboratory tests and field trials involving cats ranging in age from 5 weeks to 17 years old. The majority of cats exhibited no serious post-vaccination reactions attributable to the vaccine¹.
• Efficacy of Felocell 4 was determined by challenge-of-immunity tests. Vaccinated cats experienced significantly less severe clinical signs than non-vaccinated control cats after challenge with virulent FVR virus, FCV, FPL virus or C. felis¹.
• Results of serological studies indicated that no immunological interference existed amoong the vaccine fractions. In specific pathogen-free cats, vaccination with Felocell 4 stimulated serological titres to each of the 4 vaccine fractions¹.

Felocell 4 is packaged in freeze-dried form with inert gas in place of vacuum and available in packs of 25 x 1 mL dose vials of vaccine with diluent.

Vaccination of healthy cats is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well and administer 1 mL subcutaneously or intramuscularly.

Primary vaccination: Healthy cats 12 weeks of age or older should receive 2 doses administered 3-4 weeks apart. Cats vaccinated at less than 12 weeks of age should be revaccinated at 12 weeks of age.

Revaccination: Annual revaccination with a single dose is recommended.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitised, are stressed due to shipment or environmental conditions, are otherwise immuno-compromised, or the vaccine is not administered in accordance with label directions.

1. Store at 2-8ºC (Refrigerate, do not freeze). Prolonged exposure to higher temperatures may adversely affect potency.
2. Use entire contents when first opened.
3. Sterilised syringes and needles should be used to administer this vaccine. Do not sterilise with chemicals because traces of disinfectant may inactivate the vaccines.
4. Burn containers and all unused contents.
5. Contains gentamicin as preservative.
6. Vaccination of pregnant queens should be avoided.
7. The use of this product has been associated with fever, anorexia and lethargy in 1% of vaccinated cats, often occurring in clusters in association with multiple concurrent vaccinations. Veterinary intervention may be required. When treatment is necessary, supportive care, steroids and antibiotics have been utilised.
8. As with many vaccines, anaphylaxis may occur following use. In this event, an initial antidote of adrenaline is recommended and should be followed by appropriate supportive therapy.
9. In case of accidental human exposure, consult a physician.

Prescription Animal Remedy. Keep out of reach of children. For animal treatment only.

Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. FELOCELL is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A5694. RVM; Available only under Veterinary Authorisation.

References:

1. Felocell 4 ACVM approved label.

For technical enquiries please phone Zoetis Technical Services on 0800 650 277.

• Zoetis Safety Data Sheets
• Label: http://www.foodsafety.govt.nz/

Cats
Antibiotics, parasite control and disease prevention for cats.